HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Larry Witte Selected Research

IMC-EB10

5/2006IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
2/2005Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
8/2004Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Larry Witte Research Topics

Disease

25Neoplasms (Cancer)
06/2011 - 01/2002
9Neoplasm Metastasis (Metastasis)
02/2010 - 01/2002
6Leukemia
05/2006 - 01/2002
4Colorectal Neoplasms (Colorectal Cancer)
06/2011 - 01/2004
4Breast Neoplasms (Breast Cancer)
10/2008 - 12/2003
4Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2005 - 01/2004
2Carcinogenesis
05/2005 - 01/2004
1Renal Cell Carcinoma (Grawitz Tumor)
01/2011
1Spinocerebellar Ataxias (Spinocerebellar Ataxia)
03/2010
1Exanthema (Rash)
07/2009
1Inflammation (Inflammations)
07/2009
1Pancreatic Neoplasms (Pancreatic Cancer)
06/2009
1Hypoxia (Hypoxemia)
06/2009
1Ascites
04/2009
1Experimental Melanoma
10/2008
1Glioblastoma (Glioblastoma Multiforme)
09/2008
1Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
05/2006
1Chromosomal Instability (Chromosome Stability)
06/2004
1Adenocarcinoma
06/2004
1Pathologic Neovascularization
01/2002

Drug/Important Bio-Agent (IBA)

8Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2011 - 01/2002
8AntibodiesIBA
06/2009 - 01/2002
7ErbB Receptors (EGF Receptor)IBA
06/2011 - 01/2004
7LigandsIBA
06/2009 - 12/2003
6Monoclonal AntibodiesIBA
07/2009 - 12/2003
5Cetuximab (Erbitux)FDA Link
06/2011 - 01/2004
5Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2011 - 09/2004
5Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2011 - 01/2004
3Neutralizing AntibodiesIBA
02/2010 - 08/2004
3IMC-EB10IBA
05/2006 - 08/2004
2Pharmaceutical PreparationsIBA
06/2011 - 10/2008
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2011 - 09/2004
2Growth Factor ReceptorsIBA
01/2011 - 01/2004
2CytokinesIBA
03/2010 - 02/2010
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/2010 - 10/2008
2Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
06/2009 - 03/2005
2Angiogenesis InhibitorsIBA
06/2009 - 06/2002
2Biological ProductsIBA
04/2009 - 05/2005
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
10/2008 - 10/2006
2Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
01/2007 - 01/2005
2Mitogen-Activated Protein KinasesIBA
10/2006 - 12/2003
2Somatomedin Receptors (Somatomedin Receptor)IBA
05/2005 - 01/2004
2Epidermal Growth Factor (EGF)IBA
05/2005 - 01/2004
1DNA (Deoxyribonucleic Acid)IBA
06/2011
1Irinotecan (Camptosar)FDA LinkGeneric
06/2011
1Biomarkers (Surrogate Marker)IBA
06/2011
1Sunitinib (Sutent)FDA Link
01/2011
1Cytotoxins (Cytolysins)IBA
02/2010
1Transforming Growth Factor beta (TGF-beta)IBA
02/2010
1Phosphotransferases (Kinase)IBA
02/2010
1Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA
02/2010
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
07/2009
1Etanercept (Enbrel)FDA Link
07/2009
1cixutumumabIBA
06/2009
1Insulin (Novolin)FDA Link
06/2009
1Proteins (Proteins, Gene)FDA Link
06/2009
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
06/2009
1Conditioned Culture MediaIBA
04/2009
1Tyrosine Kinase InhibitorsIBA
04/2009
1Transforming Growth Factor alpha (TGF-alpha)IBA
04/2009
1Trastuzumab (Herceptin)FDA Link
10/2008
1Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric
10/2008
1GemcitabineFDA Link
09/2008
1Paclitaxel (Taxol)FDA LinkGeneric
09/2008
1epidermal growth factor receptor VIIIIBA
09/2008
1Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
10/2006
1Bispecific AntibodiesIBA
05/2005
1Platelet-Derived Growth Factor alpha ReceptorIBA
03/2005
1Vascular Endothelial Growth FactorsIBA
03/2005
1Vascular Endothelial Growth Factor CIBA
01/2005
1Interleukin-6 (Interleukin 6)IBA
09/2004
1Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
09/2004
1fms-Like Tyrosine Kinase 3IBA
08/2004
1Immunoglobulin G (IgG)IBA
08/2004
1ImmunosorbentsIBA
08/2004
1EnzymesIBA
08/2004
1Immunoglobulins (Immunoglobulin)IBA
08/2004
1Messenger RNA (mRNA)IBA
06/2004
1Complementary DNA (cDNA)IBA
06/2004
1N- (2,6- dimethylphenyl)- 4- (((diethylamino)acetyl)amino)benzamideIBA
06/2004
1Leucine (L-Leucine)FDA Link
06/2004
1flt3 ligand protein (flt3 ligand)IBA
01/2004
1Insulin-Like PeptidesIBA
12/2003
1IGF Type 1 Receptor (IGF 1 Receptor)IBA
12/2003
1Cell Surface ReceptorsIBA
12/2003
1Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
12/2003
1Immunoglobulin Fab FragmentsIBA
01/2002

Therapy/Procedure

8Therapeutics
06/2011 - 06/2002
4Drug Therapy (Chemotherapy)
06/2011 - 09/2008
1Transplantation
03/2010
1Injections
02/2005